Mr. Tony O'Brien:

These are two different things. The current or outgoing agreement has performed to expectation. All the savings that were envisaged for that agreement were produced, the only variance being that it kicked in six months or so later than was originally intended. It was meant to kick in either in 2012 or 2013 but did not do so until the beginning of the subsequent year. It has saved €400 million; in other words, we would have spent €400 million more for the same drugs without that agreement. Consequently, it would not be fair to state that it has not performed. Obviously, what is at stake now is that we are seeking to put in place a successor - and, incidentally, that agreement continues until the successor agreement is negotiated. What is important now is to put in place a successor agreement that delivers even more. That is what is-----